



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 11 December 2020

Re: Freedom of Information Request
Ref: 268-2020

Thank you for your email dated the 17th November, requesting information in relation to incidence and treatment of prostate and ovarian cancer.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

Please note - As we are a tertiary centre we do not diagnose patients, however, as an oncology centre, patients are referred to us with a cancer diagnosis for oncology opinion/treatment.

- 1. How many patients were diagnosed with prostate cancer over the last 3 months? Of these, how many patients were diagnosed with metastatic prostate cancer?**
Of the patients referred to our Trust for prostate cancer, 180 patients had a diagnosis date between the 1st August 2020 and 31st

October 2020. Of these, 31 presented to CCC with metastatic disease.

2. How many prostate cancer patients were treated over the last 3 months with:

- a. Docetaxel = 29 patients
- b. Abiraterone = 223 patients
- c. Enzalutamide = 212 patients
- d. Cabazitaxel = 17 patients

3. How many patients have been diagnosed with advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months. If none, do you refer ovarian cancer patients to another trust, if so which one?

Of the patients referred to our Trust for Ovarian cancer with a diagnosis date between the 1st August 2020 and 31st October 2020, 14 patients presented to CCC with stage III and IV.

4. Of the ovarian cancer patients diagnosed over the last 3 months, how many have been treated with:

Of the patients referred to our Trust with Ovarian cancer during this time period the requested treatment figures are as follows:

- a. Paclitaxel in combination with a platinum-based compound = 9 patients
- b. Platinum-based therapy alone (cisplatin or carboplatin) = 6 patients
- c. Bevacizumab in combination with paclitaxel and carboplatin = Exempt under S.40
- d. Olaparib = 0 patients
- e. Niraparib = 0 patients
- f. Rucaparib = 0 patients

5. **Of the ovarian cancer patients diagnosed over the last 3 months, how many have been tested for the BRCA mutation? And of these, how many tested positive?**

Of the patients referred to our Trust with Ovarian cancer during this time period, 16 patients consented for BRCA testing. The figures for these patients are as follows:

Positive = Exempt under S.40

Negative = Exempt under S.40

Insufficient sample = Exempt under S.40

Not yet reported = 6 patients

BRCA testing not complete = Exempt under S.40

6. **Of the ovarian cancer patients who were positive for a BRCA mutation, how many patients received**
- a. **Olaparib for 1st line maintenance = 0 patients**
 - b. **Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance = 0 patients**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be

addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre
NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you
have the right to apply directly to the Information Commissioner for a decision.
The Information Commissioner can be contacted at: Information Commissioner's
Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.